← Leaderboards
Neil E Kay
Mayo Clinic Coll Of Medicine, Rochester
$14,251,394
Attributed
$18,282,998
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,282,998 · 10
By mechanism
R01$17,093,580 · 6
R21$1,170,681 · 3
M01$18,737 · 1
Top collaborators
- Tait D Shanafelt13 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- James R Cerhan$31,221,407
- Rafael Fonseca$16,992,958
- Gregory J. Gores$22,244,646
- Richard M Goldberg$4,114,970
Others in their field
Top investigators on “Chronic Lymphocytic Leukemia”
- David Heimbrook · Leidos Biomedical Research, Inc.$30,232,142
- Catherine Ju-Ying Wu · Broad Institute, Inc.$27,924,233
- John C Byrd · University Of Cincinnati$23,347,401
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Susan L Slager · Mayo Clinic Rochester$15,712,869
- Thomas J. Kipps · University Of California San Diego$14,051,126
Research focus
Chronic Lymphocytic LeukemiaDisease ProgressionCyclophosphamideCohortBasePathway InteractionsResponseAngiogenesisRelapseCellsMutationToxic EffectRituximabGeneticStratificationResistanceVascular Endothelial Growth FactorsB-LymphocytesGene ExpressionInsightDesignDrug ResistanceApoptosisCombined Modality Therapy
Grant awards (43)
Outcomes for CLL patients treated with novel therapy$671,624
R01 · FY2025 · CA · contact PI
Outcomes for CLL patients treated with novel therapy$596,539
R01 · FY2024 · CA · contact PI
Outcomes for CLL patients treated with novel therapy$614,982
R01 · FY2023 · CA · contact PI
Outcomes for CLL patients treated with novel therapy$616,831
R01 · FY2022 · CA · contact PI
Outcomes for CLL patients treated with novel therapy$705,542
R01 · FY2021 · CA · contact PI
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$634,568
R01 · FY2019 · CA · contact PI
Predicting clinical outcome in individuals with small CLL B cell clones$584,454
R01 · FY2019 · CA · contact PI
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$691,685
R01 · FY2018 · CA · contact PI
Predicting clinical outcome in individuals with small CLL B cell clones$603,908
R01 · FY2018 · CA · contact PI
Predicting clinical outcome in individuals with small CLL B cell clones$605,286
R01 · FY2017 · CA · contact PI
Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia$510,400
R01 · FY2017 · CA · contact PI
Predicting clinical outcome in individuals with small CLL B cell clones$611,624
R01 · FY2016 · CA
Predicting clinical outcome in individuals with small CLL B cell clones$615,766
R01 · FY2015 · CA
Combination Therapy in B-Chronic Lymphocytic Leukemia$451,725
R01 · FY2012 · CA · contact PI
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia$282,571
R01 · FY2011 · CA · contact PI
Combination Therapy in B-Chronic Lymphocytic Leukemia$119,869
R01 · FY2011 · CA · contact PI
Combination Therapy in B-Chronic Lymphocytic Leukemia$603,916
R01 · FY2010 · CA · contact PI
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia$401,851
R01 · FY2010 · CA · contact PI
VEGF Function in B-CLL$271,511
R01 · FY2010 · CA · contact PI
Combination Therapy in B-Chronic Lymphocytic Leukemia$599,968
R01 · FY2009 · CA · contact PI
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia$405,110
R01 · FY2009 · CA · contact PI
VEGF Function in B-CLL$268,755
R01 · FY2009 · CA · contact PI
Combination Therapy in B-Chronic Lymphocytic Leukemia$597,549
R01 · FY2008 · CA · contact PI
VEGF Function in B-CLL$263,498
R01 · FY2008 · CA · contact PI
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia$101,766
R01 · FY2008 · CA · contact PI
Chemo-Immunotherapy in Relapsed/Refactory B-Chronic Lymphocytic Leukemia$395,110
R01 · FY2007 · CA · contact PI
VEGF Function in B-CLL$263,509
R01 · FY2007 · CA · contact PI
B-CLL Biology: Impact of Combination Therapy$744,412
R01 · FY2006 · CA · contact PI
Impact of Chemo-Immunotherapy in Relapsed/Refactory B-CLL$394,311
R01 · FY2006 · CA · contact PI
VEGF Function in B-CLL$264,846
R01 · FY2006 · CA · contact PI
B-CLL Biology: Impact of Combination Therapy$756,345
R01 · FY2005 · CA
CYCLOPHOSPHAMIDE, PENTOSTATIN, AND RITUXIMAB-LEUKEMIA OR LYMPHOMA$9,004
M01 · FY2005 · RR
B-CLL Biology: Impact of Combination Therapy$749,408
R01 · FY2004 · CA
B-CLL Biology: Impact of Combination Therapy$207,763
R01 · FY2004 · CA
Cyclophosphamide/Pentostatin/Rituximab for untreated CLL$9,733
M01 · FY2004 · RR
B-CLL Biology: Impact of Combination Therapy$436,610
R01 · FY2003 · CA
B-CLL Biology: Impact of Combination Therapy$449,968
R01 · FY2002 · CA
B CLL Subtypes--Correlation with Clinical Outcome$317,475
R21 · FY2002 · CA
Angiogenesis in B Chronic Lymphocytic Leukemia$141,100
R21 · FY2002 · CA
B CLL Subtypes--Correlation with Clinical Outcome$315,995
R21 · FY2001 · CA
Angiogenesis in B Chronic Lymphocytic Leukemia$140,237
R21 · FY2001 · CA
IMPACT OF DONOR LYMPHOCYTE INFUSIONS ON MYELOMA PATIENTS$117,525
R21 · FY2001 · CA
IMPACT OF DONOR LYMPHOCYTE INFUSIONS ON MYELOMA PATIENTS$138,349
R21 · FY2000 · CA